DDX53 and neoplasm: To determine whether mice with complete CT26 tumor regression were protected from rechallenge with the same tumor, we rechallenged CT26 tumor–bearing mice from those treated with single doses of GITRL-FP at 1.0, 0.5, or 0.2 mg/kg (Fig. 4a).